BERLIN
CH KILGER Anwaltspartnerschaft mbB
Fasanenstraße 29
10719 Berlin, Germany
t +49 30 886 20 07 – 0
f +49 30 886 20 07 – 10
berlin@chkilger.com
MUNICH
CH KILGER Anwaltspartnerschaft mbB
c/o Huber & Schüssler
Truderinger Strasse 246
81825 Munich
Germany
schuessler@chkilger.com
BUENOS AIRES
CH KILGER Anwaltspartnerschaft mbB
c/o Estudio Domma
Uruguay 390 piso 15 of., “c”
Capital Federal
Buenos Aires, Argentina
marazzi@chkilger.com
MEXICO
CH KILGER Anwaltspartnerschaft mbB
c/o WJS
Col. Centro
Cuernavaca, Morelos
C.P. 62001
MEXICO
marazzi@chkilger.com
12/2019
3 in ONE STRIKE – ILLUMINA PATENTS INVALIDATED BY CH KILGER
The European Patent Office has destroyed several patents belonging to Illumina, a US manufacturer of DNA sequencing machine and a market leader in the field.
阅读更多
01/2019
CH KILGER WINS CLIENT CHOICE AWARD
For the second time after 2013 the law firm has received this prestigious award now in 2019. We thank our clients for their continuous trust. We will thrive to be even better in 2020.unique design.
What clients said:
“He has kept his curiosity and is a sure bet if you need creative solutions to complex problems. He does not live in an ivory tower and as such delivers not only creative but also realistic solutions.”
“Because of his work and exceptional performance, I rate him extremely high for his competence, reliability and loyalty to our company, and for carrying out work at very high quality and, if necessary, at very short notice.”
“He has been an indispensable expert in securing IP rights and patent claims and supporting us on numerous levels in evaluating IP-related contracts and projects. He has exceptional communication skills that are essential in negotiations with other companies.”
“Dr Kilger, in comparison to other firms and attorneys, has outstanding expertise and commercial awareness, especially in the field of healthcare and life sciences.”
09/2018
Why patent attorneys love 911s
(District Court 17 O 1324/17)
Some of us patent attorneys are also car aficionados. It is claimed that one or the other patent attorney has a 911 Porsche in the garage. The enthusiasm for the 911 may be due to the absolutely unique design. This design has now become the subject matter of a copyright dispute (17 O 1324/17) before the district court of Stuttgart. 阅读更多
08/2018
T2563/11 –
EPO Decision by the Technical Board of Appeal 3.3.1
As you will know the issue of double patenting is not codified expressis verbis in the EPC. Some case law has dealt with this though (G 1/05 and G 1/06). 阅读更多
05/2018
Lionel Andrés Messi Wins
Lionel Andrés Messi wins at the General Court of the European Union (EGC) and succeeds in getting his trademark M.E.S.S.I registered. Filed in 2011 a third party owning an older trademark „MASSI““ had objected against the registration. The „soccer player’s fame counteracts the visual and phonetic similarities“.
UK Ratifies UPC Agreement
The British Government has announced on April 26, 2018 that it has ratified the UPC Agreement. This means it will be bound also to the UPC’s Protocol on Privileges and Immunities (PPI). Concerning issues of EU law the UPC system will need to refer to the ECJ. A cheap price to pay for by the UK considering, that estimates say the move will bring the British legal system as much as 300 Mio Euros worth of business a year. Whether this ratification means the Court will remain in London, outside of the EU after BREXIT, is to be seen though.
01/2018
CH KILGER wins 2017 legal awards from LAWYER MONTHLY as Patent Law Firm of the Year in Germany.
08/2017
COMPULSORY LICENSE DECISION UPHELD BY GERMAN FEDERAL COURT OF JUSTICE
Compulsory licenses are really very rare! The German Federal Court of Justice (BGH) has now upheld the decision by the German Federal Patent Court (BPatG) granting Merck a license to Shionogi’s patent EP 1 422 218 B1 covering the HIV drug “Isentress”, as sold by Merck.
License negotiations had gone sour and Shionogi sued Merck for patent infringement (No. 4c O 48/15). This proceeding was stayed as there is an ongoing opposition/appeal at the EPO (T 1150/15) for which oral proceedings have been scheduled for October 2017. In the meantime, Merck requested a compulsory license which was, in a first instance, granted by the BPatG and now upheld by the BGH.